Pharmacokinetics of HIV-Integrase Inhibitors During Pregnancy: Mechanisms, Clinical Implications and Knowledge Gaps

Dolutegravir pharmacokinetics in pregnant and postpartum women living with HIV

(2018) Nikki Mulligan et al.   AIDS

Cost-effectiveness of public-health policy options in the presence of pretreatment NNRTI drug resistance in sub-Saharan Africa: a modelling study

(2018) Andrew N Phillips et al.   Lancet HIV

Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial

(2017) David A Margolis et al.   LANCET

High plasma concentrations of dolutegravir in patients with ABCG2 genetic variants

(2017) Kiyoto Tsuchiya et al.   Pharmacogenetics and Genomics

First reported use of elvitegravir and cobicistat during pregnancy

(2016) Stein Schalkwijk et al.   AIDS

Substantially lowered dolutegravir exposure in a treatment-experienced perinatally HIV-1-infected pregnant woman

(2016) Stein Schalkwijk et al.   AIDS

P-glycoprotein (ABCB1) activity decreases raltegravir disposition in primary CD4+P-gphighcells and correlates with HIV-1 viral load

(2016) Gerard Minuesa et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

17 β -Estradiol up-regulates UDP-glucuronosyltransferase 1A9 expression via estrogen receptor α

(2016) Sung-joon Cho et al.   Acta Pharmaceutica Sinica B

Population pharmacokinetics of dolutegravir in HIV-infected treatment-naive patients

(2015) Jianping Zhang et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Raltegravir in HIV-1–Infected Pregnant Women: Pharmacokinetics, Safety, and Efficacy

(2015) Maren I. Blonk et al.   CLINICAL INFECTIOUS DISEASES

Drug interaction profile of the HIV integrase inhibitor cabotegravir: assessment fromin vitrostudies and a clinical investigation with midazolam

(2015) Melinda J. Reese et al.   XENOBIOTICA

Disposition and metabolism of cabotegravir: a comparison of biotransformation and excretion between different species and routes of administration in humans

(2015) Gary David Bowers et al.   XENOBIOTICA

Formulation and pharmacology of long-acting cabotegravir

(2015) Christine Trezza et al.   Current Opinion in HIV and AIDS

Pharmacokinetics and Safety of Boosted Elvitegravir in Subjects with Hepatic Impairment

(2014) J. M. Custodio et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Pregnancy influences the plasma pharmacokinetics but not the cerebrospinal fluid pharmacokinetics of raltegravir: A preclinical investigation

(2014) Mahamad Yunnus A. Mahat et al.   EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES

Alteration in cytochrome P450 3A4 activity as measured by a urine cortisol assay in HIV-1-infected pregnant women and relationship to antiretroviral pharmacokinetics

(2014) FT Aweeka et al.   HIV MEDICINE

Raltegravir Pharmacokinetics During Pregnancy

(2014) D. Heather Watts et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Metabolism, Excretion, and Mass Balance of the HIV-1 Integrase Inhibitor Dolutegravir in Humans

(2013) Stephen Castellino et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Characterization of Binding of Raltegravir to Plasma Proteins

(2013) Caroline Barau et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Role of P-glycoprotein in the efflux of raltegravir from human intestinal cells and CD4+ T-cells as an interaction target for anti-HIV agents

(2013) Yumi Hashiguchi et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Influence of Gestational Age and Body Weight on the Pharmacokinetics of Labetalol in Pregnancy

(2013) James H. Fischer et al.   CLINICAL PHARMACOKINETICS

Clinical Pharmacokinetic, Pharmacodynamic and Drug-Interaction Profile of the Integrase Inhibitor Dolutegravir

(2013) Mackenzie L. Cottrell et al.   CLINICAL PHARMACOKINETICS

Clinical Use of HIV Integrase Inhibitors: A Systematic Review and Meta-Analysis

(2013) Peter Messiaen et al.   PLoS One

Comparison of theIn VivoPharmacokinetics andIn VitroDissolution of Raltegravir in HIV Patients Receiving the Drug by Swallowing or by Chewing

(2012) Dario Cattaneo et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Pharmacokinetics and Pharmacodynamics of Once-Daily versus Twice-Daily Raltegravir in Treatment-Naïve HIV-Infected Patients

(2012) Matthew L. Rizk et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Cobicistat Boosts the Intestinal Absorption of Transport Substrates, Including HIV Protease Inhibitors and GS-7340,In Vitro

(2012) Eve-Irene Lepist et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Pharmacokinetics of paracetamol and its metabolites in women at delivery and post-partum

(2012) Aida Kulo et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Anatomical, Physiological and Metabolic Changes with Gestational Age during Normal Pregnancy

(2012) Khaled Abduljalil et al.   CLINICAL PHARMACOKINETICS

Pregnane-x-receptor controls hepatic glucuronidation during pregnancy and neonatal development in humanized UGT1 mice

(2012) Shujuan Chen et al.   HEPATOLOGY

Safety, Tolerability, and Pharmacokinetics of the HIV Integrase Inhibitor Dolutegravir Given Twice Daily With Rifampin or Once Daily With Rifabutin

(2012) Kelly E. Dooley et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of dolutegravir as 10-day monotherapy in HIV-1-infected adults

(2011) Sherene Min et al.   AIDS

Plasma Raltegravir Exposure Influences the Antiviral Activity and Selection of Resistance Mutations

(2011) Carolina Garrido et al.   AIDS RESEARCH AND HUMAN RETROVIRUSES

Pharmacokinetic Modeling of Plasma and Intracellular Concentrations of Raltegravir in Healthy Volunteers

(2011) Lingzhi Wang et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Clinical Pharmacokinetic and Pharmacodynamic Profile of the HIV Integrase Inhibitor Elvitegravir

(2011) Srinivasan Ramanathan et al.   CLINICAL PHARMACOKINETICS

Potential of novel antiretrovirals to modulate expression and function of drug transporters in vitro

(2011) N. C. L. Zembruski et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non-inferiority trial

(2011) Joseph J Eron et al.   LANCET INFECTIOUS DISEASES

Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial

(2011) Jan van Lunzen et al.   LANCET INFECTIOUS DISEASES

In VitroAntiretroviral Properties of S/GSK1349572, a Next-Generation HIV Integrase Inhibitor

(2010) Masanori Kobayashi et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

The effect of liver disease on inhibitory and plasma protein-binding displacement interactions: an update

(2010) Pietro Palatini et al.   Expert Opinion on Drug Metabolism & Toxicology

Pharmacokinetics and Bioavailability of an Integrase and Novel Pharmacoenhancer-Containing Single-Tablet Fixed-Dose Combination Regimen for the Treatment of HIV

(2010) Polina German et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Cobicistat (GS-9350): A Potent and Selective Inhibitor of Human CYP3A as a Novel Pharmacoenhancer

(2010) Lianhong Xu et al.   ACS Medicinal Chemistry Letters

Pharmacokinetics of Raltegravir in Individuals With UGT1A1 Polymorphisms

(2009) LA Wenning et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Effect of Pregnancy on Cytochrome P450 3a and P-Glycoprotein Expression and Activity in the Mouse: Mechanisms, Tissue Specificity, and Time Course

(2008) H. Zhang et al.   MOLECULAR PHARMACOLOGY

Regulation of UDP-glucuronosyltransferase (UGT) 1A1 by progesterone and its impact on labetalol elimination

(2007) H. Jeong et al.   XENOBIOTICA